MPM Oncology Impact Management »

Trevi Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Trevi Therapeutics (TRVI) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Trevi Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Trevi Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Trevi Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $4.5M 1.5M 2.98
2024-03-31 $4.6M 1.3M 3.45

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Trevi Therapeutics

NEA Management Company
Frazier Life Sciences Management
Rubric Capital Management
Viking Global Investors
VR Adviser
BlackRock
Logos Global Management
Opaleye Management
Vanguard Group
MPM Oncology Impact Management
MAI Wealth Advisors
Geode Capital Management
State Street Corporation
Silverarc Capital Management
Rosalind Advisors

View all funds holding Trevi Therapeutics